Pioneer Fund

Curacel is an insurtech company founded in 2019 by Henry Mascot in Ikoyi, Lagos. It offers an AI-powered platform designed to streamline and enhance the insurance claims process. The platform automates the processing of claims, enabling insurance staff to handle higher volumes efficiently. Additionally, it incorporates advanced algorithms for fraud detection, waste, and abuse management, ensuring that claims are thoroughly vetted. Curacel's technology integrates seamlessly with various systems and third-party applications, facilitating improved operational efficiency for insurance providers while fostering customer loyalty and retention.

Curacel is an insurtech company founded in 2019 by Henry Mascot in Ikoyi, Lagos. It offers an AI-powered platform designed to streamline and enhance the insurance claims process. The platform automates the processing of claims, enabling insurance staff to handle higher volumes efficiently. Additionally, it incorporates advanced algorithms for fraud detection, waste, and abuse management, ensuring that claims are thoroughly vetted. Curacel's technology integrates seamlessly with various systems and third-party applications, facilitating improved operational efficiency for insurance providers while fostering customer loyalty and retention.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.

54gene is a biotechnology company founded in 2019 and headquartered in San Francisco, California, with additional offices in Lagos, Nigeria. The company focuses on unlocking the potential of the African genome to enhance genetic research and development, addressing a significant gap in the global genomics market where a majority of genetic data is derived from individuals of Caucasian descent. By developing a pan-African biobank, 54gene aims to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular conditions, and neurodegenerative disorders. In addition to its research initiatives, the company offers genetic testing and molecular diagnostics services to patients and healthcare providers, ensuring compliance with international data privacy laws. Through its efforts, 54gene seeks to contribute to the discovery of medical advancements that can benefit diverse populations.